Molecular testing transformed diagnostics — but in much of Africa it remains locked inside central reference laboratories, with samples travelling long distances and results arriving days later. Point-of-care molecular testing changes that equation: automated nucleic acid detection at or near the patient makes rapid, decentralised testing feasible for clinics, screening programmes and smaller laboratories.
Why decentralised molecular testing matters
Rapid detection at the point of care removes the transport step to a central laboratory. That means faster clinical decisions, earlier isolation or treatment where relevant, and testing capacity that does not depend on a single distant facility. Per official manufacturer listings, molecular POCT platforms now span healthcare, veterinary, environmental and food-safety applications — evidence of how broadly the technology is being adopted.
The Bioer CentriDx
The Bioer CentriDx is an automated nucleic acid detection analyzer for molecular point-of-care testing, presented in the Instrument Center of Bioer's official product catalogue. It is positioned for rapid detection at the point of care, suitable for clinics, decentralised laboratories and screening programmes.
Planning a POCT deployment
Programmes adopting molecular POCT should plan for: test menu definition, quality management for near-patient testing, operator training, and supply arrangements for consumables. Where results guide public-health decisions, confirm assay performance characteristics against official documentation before deployment.
How KRIMS helps
KRIMS Meditech Solutions sources molecular diagnostic instruments from verified original manufacturers such as Bioer and supports programmes across Africa with procurement, installation and commissioning. To request a quotation for the CentriDx, request a quote through KRIMS.
